Completed PHASE1 INTERVENTIONAL 2-arm NCT00863174

A Bioequivalence Study of SPARC_147709 in Patients With Multiple Myeloma

A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of SPARC_147709- Test and Reference, 2mg/ml (30 mg/m2 Dose) in Patients With Multiple Myeloma

Sponsor: Sun Pharma Advanced Research Company Limited

Conditions Multiple Myeloma

Interventions Reference147709 SPARC147709

Updated 8 times since 2017 Last updated: May 2, 2019 Started: Nov 30, 2010 Primary completion: Jan 31, 2011 Completion: Apr 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00863174, this PHASE1 trial focuses on Multiple Myeloma and remains completed. Sponsored by Sun Pharma Advanced Research Company Limited, it has been updated 8 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2019 — Jan 2021 [monthly]

Completed PHASE1
Dec 2018 — Jun 2019 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jun 2018 — Dec 2018 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Nov 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sun Pharma Advanced Research Company Limited

Data source: Sun Pharma Advanced Research Company Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.